Stocks and Investing Stocks and Investing
Mon, October 14, 2019
Fri, October 11, 2019

Matthew Harrison Maintained (SRPT) at Buy with Decreased Target to $160 on, Oct 11th, 2019


Published on 2024-10-26 16:52:31 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $220 to $160 on, Oct 11th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matthew


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $180 on, Friday, September 27th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $201 on, Tuesday, August 20th, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019

Contributing Sources